Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential.

Van de Putte M, Marysael T, Fonge H, Roskams T, Cona MM, Li J, Bormans G, Verbruggen A, Ni Y, de Witte PA.

Int J Cancer. 2012 Jul 15;131(2):E129-37. doi: 10.1002/ijc.26492. Epub 2012 Jan 11.

2.

Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.

Jiang B, Wang J, Ni Y, Chen F.

Theranostics. 2013 Aug 10;3(9):667-76. doi: 10.7150/thno.6650. eCollection 2013. Review.

3.

Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent.

Fonge H, Jin L, Wang H, Ni Y, Bormans G, Verbruggen A.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):4001-5. Epub 2007 Apr 30.

PMID:
17507220
4.

First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent.

Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM, Bormans GM.

Eur J Nucl Med Mol Imaging. 2006 May;33(5):595-601. Epub 2006 Feb 1.

PMID:
16450141
5.

Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model.

Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y.

Acad Radiol. 2008 Jan;15(1):107-13.

PMID:
18078913
6.

Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor.

Fonge H, Van de Putte M, Huyghe D, Bormans G, Ni Y, de Witte P, Verbruggen A.

Contrast Media Mol Imaging. 2007 May-Jun;2(3):113-9.

PMID:
17546702
7.

Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model.

Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y.

Oncol Rep. 2008 Apr;19(4):927-32.

PMID:
18357377
8.

Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.

Van de Putte M, Ni Y, De Witte PA.

Oncol Rep. 2008 Apr;19(4):921-6.

PMID:
18357376
9.

Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.

Li J, Cona MM, Chen F, Feng Y, Zhou L, Zhang G, Nuyts J, de Witte P, Zhang J, Yu J, Oyen R, Verbruggen A, Ni Y.

Theranostics. 2013;3(2):127-37. doi: 10.7150/thno.5790. Epub 2013 Feb 13.

10.

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.

Liu W, Zhang D, Feng Y, Li Y, Huang D, Jiang C, Gao M, Peng F, Wang X, Jing S, Jiang X, Ni Y, Zhang J.

J Drug Target. 2015 May;23(4):371-9. doi: 10.3109/1061186X.2014.1000337. Epub 2015 Jan 9.

PMID:
25572455
11.

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations.

Cona MM, Li J, Feng Y, Chen F, Verbruggen A, Witte Pd, Oyen R, Ni Y.

Anticancer Agents Med Chem. 2014;14(6):852-61.

PMID:
24102315
12.

Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.

Liu X, Jiang C, Zhang D, Gao M, Peng F, Huang D, Sun Z, Ni Y, Zhang J, Yin Z.

Oncotarget. 2015 Sep 22;6(28):26400-10. doi: 10.18632/oncotarget.4568.

13.

A novel method for the detection of necrotic lesions in human cancers.

Epstein AL, Chen FM, Taylor CR.

Cancer Res. 1988 Oct 15;48(20):5842-8.

14.

Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model.

Chen B, Roskams T, Xu Y, Agostinis P, de Witte PA.

Int J Cancer. 2002 Mar 10;98(2):284-90.

15.

Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.

Cona MM, Alpizar YA, Li J, Bauwens M, Feng Y, Sun Z, Zhang J, Chen F, Talavera K, de Witte P, Verbruggen A, Oyen R, Ni Y.

Pharm Res. 2014 Feb;31(2):278-90. doi: 10.1007/s11095-013-1159-4. Epub 2013 Aug 9.

PMID:
23934256
16.

Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction.

Cona MM, Feng Y, Zhang J, Li Y, Verbruggen A, Oyen R, Ni Y.

Drug Deliv. 2015 May;22(3):427-35. doi: 10.3109/10717544.2013.873838. Epub 2014 Jan 13.

PMID:
24417698
17.

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.

Marysael T, Bauwens M, Ni Y, Bormans G, Rozenski J, de Witte P.

Invest New Drugs. 2012 Dec;30(6):2132-40. doi: 10.1007/s10637-011-9778-2. Epub 2011 Dec 21.

PMID:
22187204
18.

Radiopharmaceutical evaluation of (131)I-protohypericin as a necrosis avid compound.

Liu X, Feng Y, Jiang C, Lou B, Li Y, Liu W, Yao N, Gao M, Ji Y, Wang Q, Huang D, Yin Z, Sun Z, Ni Y, Zhang J.

J Drug Target. 2015 Jun;23(5):417-26. doi: 10.3109/1061186X.2014.1002787. Epub 2015 Feb 6.

PMID:
25655506
19.

Synthesis and Preclinical Evaluation of Radioiodinated Hypericin Dicarboxylic Acid as a Necrosis Avid Agent in Rat Models of Induced Hepatic, Muscular, and Myocardial Necroses.

Li J, Zhang J, Yang S, Jiang C, Zhang D, Jin Q, Wang Q, Wang C, Ni Y, Yin Z, Song S.

Mol Pharm. 2016 Jan 4;13(1):232-40. doi: 10.1021/acs.molpharmaceut.5b00686. Epub 2015 Dec 10.

PMID:
26568406
20.

Supplemental Content

Support Center